Inhibition of growth of primary human tumour cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinases

By Baguley B.C.   Marshall E.S.   Holdaway K.M.   Rewcastle G.W.   Denny W.A.  

European Journal of Cancer, Vol. 34, Iss. 7, 1998-06 ,pp. : 1086-1090

Elsevier

Access to resources Recommend Favorite

Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives

By Ronellenfitsch Michael  

Targeted Oncology, Vol. 5, Iss. 3, 2010-09 ,pp. : 183-191

Springer Publishing Company

Access to resources Recommend Favorite

Evaluation of Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

By Rae James M.  

Breast Cancer Research and Treatment, Vol. 83, Iss. 2, 2004-01 ,pp. : 99-107

Springer Publishing Company

Access to resources Recommend Favorite

Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies

By Carrera S.   Buque A.   Azkona E.   Aresti U.   Calvo B.   Sancho A.   Arruti M.   Nuño M.   Rubio I.   Lobera A.   Lopez C.   Vivanco G.  

Clinical and Translational Oncology, Vol. 16, Iss. 4, 2014-04 ,pp. : 339-350

Springer Publishing Company

Access to resources Recommend Favorite

Differential efficacy of docetaxel according to nonsmall cell lung cancer histology and the therapeutic effect of epidermal growth factor receptor tyrosine kinase inhibitors

By                                

Oncology Letters, Vol. 2, Iss. 6, 2011-01 ,pp. : 1059-1064

Spandidos Publications

Access to resources Recommend Favorite